Analyst Price Target is $14.00
▲ +224.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for PolyPid in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 224.45% upside from the last price of $4.32.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in PolyPid. This Buy consensus rating has held steady for over two years.
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Read More